CN114540309A - Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof - Google Patents
Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof Download PDFInfo
- Publication number
- CN114540309A CN114540309A CN202210047605.0A CN202210047605A CN114540309A CN 114540309 A CN114540309 A CN 114540309A CN 202210047605 A CN202210047605 A CN 202210047605A CN 114540309 A CN114540309 A CN 114540309A
- Authority
- CN
- China
- Prior art keywords
- cell
- virus
- recombinant
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001493065 dsRNA viruses Species 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000003321 amplification Effects 0.000 title claims abstract description 16
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 93
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 18
- 108700025694 p53 Genes Proteins 0.000 claims abstract description 14
- 238000012217 deletion Methods 0.000 claims abstract description 5
- 230000037430 deletion Effects 0.000 claims abstract description 5
- 230000000415 inactivating effect Effects 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 32
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 15
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 14
- 101100406320 Caenorhabditis elegans dbt-1 gene Proteins 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 13
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000003209 gene knockout Methods 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 238000003113 dilution method Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241000711975 Vesicular stomatitis virus Species 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000711404 Avian avulavirus 1 Species 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000021601 lentivirus infection Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YZEZMSPGIPTEBA-UHFFFAOYSA-N 2-n-(4,6-diamino-1,3,5-triazin-2-yl)-1,3,5-triazine-2,4,6-triamine Chemical compound NC1=NC(N)=NC(NC=2N=C(N)N=C(N)N=2)=N1 YZEZMSPGIPTEBA-UHFFFAOYSA-N 0.000 description 1
- 102000000131 Beta tubulin Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 description 1
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 1
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 description 1
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101710084021 Large envelope protein Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000012570 Opti-MEM I medium Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
- C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
- C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a recombinant cell for efficiently amplifying RNA virus, an amplification method and application thereof, and relates to the technical field of genetic engineering, wherein the recombinant cell is a eukaryotic cell with p53 gene expression deletion, which is prepared by inactivating a p53 gene in the eukaryotic cell.
Description
Technical Field
The invention relates to the technical field of genetic engineering, in particular to a recombinant cell for efficiently amplifying RNA virus, an amplification method and application thereof.
Background
Malignant infectious diseases caused by RNA viruses, such as coronavirus, influenza virus and the like, seriously harm human life health. The research on the infection mechanism and biological characteristics of the malignant infectious viruses and the research and development of high-efficiency antiviral drugs become research hotspots, and the separation and high-efficiency amplification of the viruses become the basis of scientific research, drug screening and vaccine development. Therefore, efficient propagation of viruses becomes an important key element. The amplified viruses mainly comprise: animal inoculation, chick embryo inoculation and cell culture methods. Animal vaccination is limited in scope and may be confused with potential viruses in animals; chick embryo inoculation often cannot produce specific infection indexes, and is also limited by the range and scale of the virus which can be inoculated; the culture of the cells can be artificially controlled, and the samples are relatively uniform and have strong probabilityof. At present, astrocyte cell lines DBT-1, Vero and human lung cancer cell lines A549 and the like are commonly used as platform cells for in vitro virus infection screening drug and vaccine development.
To further improve the virus amplification capacity of these cells, we can modify the platform cells by gene editing technology. Cells cultured in vitro also have an innate immune response, and the presence of this immunity affects further propagation of the virus; at the same time, the immune response can mediate cell death (mainly in the form of apoptosis), which also affects the ultimate viral replication. According to research, we found that the tumor suppressor gene p53 plays an important role and function in the infection process of viruses. The protein coded by the gene has wide and important biological effects, and regulates and controls the processes of cell cycle, apoptosis, genome stability maintenance, virus infection inhibition and the like. During the course of resisting viral infection, p53 can regulate various immune regulatory genes, including TLR3, IRF9, IRF5, PKR and ISG15, etc. Therefore, p53 becomes a potential target gene for efficient amplification of viruses.
At present, the gene editing technology is developed very rapidly, and particularly, the CRISPR-Cas9 nuclease system has the characteristics of high efficiency and high speed of gene editing. Under the action of the specific guide RNA, Cas9 nuclease can cleave DNA double strands at specific positions to form Double Strand Breaks (DSBs), and then edit the segment of interest using homologous directed repair or non-homologous end-joining repair methods, thereby generating gene knockouts or mutations.
Based on the above, the p53 gene in the virus amplification cell is knocked out by using the CRISPR-Cas9 technology, so as to construct a platform cell for further efficiently amplifying the virus. Therefore, a recombinant cell for efficiently amplifying RNA virus, an amplification method and application thereof are provided.
Disclosure of Invention
The invention aims to provide a method for efficiently amplifying viruses based on a CRISPR-Cas9 editing technology, and expands the application of the method in efficiently amplifying the viruses.
The invention realizes the purpose through the following technical scheme:
the invention provides a recombinant cell for efficiently amplifying RNA viruses, which is a eukaryotic cell with p53 gene expression deletion and is prepared by inactivating p53 gene in the eukaryotic cell.
The further improvement is that the eukaryotic cell is a Vero cell or a DBT-1 cell.
The further improvement is that the recombinant cell is characterized in that the 4 th exon sequence of the p53 gene is mutated, the 4 th exon sequence comprises a nucleotide sequence shown as SEQ ID NO.1, and the mutation is deletion or addition of at least 1 base in the nucleotide sequence shown as SEQ ID NO. 1.
The further improvement is that the mutation is the nucleotide sequence shown in SEQ ID NO.1 and is edited into a sequence shown in any one of SEQ ID NO. 2-4.
The further improvement is that p53 gene in eukaryotic cells is inactivated by gene knockout means, the gene knockout means adopts CRISPR-Cas9 technology, and the steps comprise:
(1) the coding region of an exon of a eukaryotic cell p53 gene is used as a template, and a specifically targeted sgRNA sequence is designed according to CRISPR-Cas9 technical requirements and sequence homology comparison analysis;
(2) synthesizing double-stranded DNA of knockout p53 according to the sgRNA sequence, and connecting the double-stranded DNA to pSpCas9(BB) -2A-Puro plasmid to obtain a recombinant plasmid;
(3) transfecting the recombinant plasmid into a eukaryotic cell, and screening a cell strain with significantly reduced expression of p 53;
(4) and (3) obtaining the monoclonal cell with p53 knocked out by a pressure screening and limiting dilution method, namely the recombinant cell.
In a further improvement, the eukaryotic cell is a DBT-1 cell, the sequence of sg RNA specifically targeted in step (1) is 5'-AGTGAAGCCCTCCGAGTGTC-3', and the sequence of the double-stranded DNA in step (2) is oligo 1: 5'-CACCGCCTCGAGCTCCCTCTGAGCC-3', respectively; oligo 2: 5'-AAACGGCTCAGAGGGAGCTCGAGGC-3' are provided.
The invention also provides a method for efficiently amplifying the RNA virus by using the recombinant cell, which is used for infecting the recombinant cell by using the virus so as to improve the titer of the virus and realize efficient amplification.
In a further improvement, the RNA virus is a lentivirus.
In a further improvement, the lentivirus is a VSV virus or NDV virus.
The invention also provides the application of the recombinant cell in high-efficiency amplification of RNA viruses and production and development of the RNA virus vaccines.
The invention has the following beneficial effects:
according to the invention, the p53 inactivated recombinant cell is obtained in the eukaryotic cell by a gene knockout means, the titer of the corresponding virus can be improved after the cell is infected with the virus, and the virus with the significantly improved titer can be VSV, NDV or other RNA viruses, and can be used for the research and development and production processes of corresponding vaccines.
Drawings
Fig. 1 shows the targeting positions of 4 sgrnas in the exon of p 53.
FIG. 2 shows the expression of p53 after 4 sgRNA expression plasmids were transfected into DBT-1 cells.
FIG. 3 shows the identification of knockout cells.
FIG. 4 shows the proliferation of a knockout cell.
FIG. 5 is a case of knockdown cells against apoptosis.
FIG. 6 is a fluorescence intensity analysis after infection of cells with lentivirus.
FIG. 7 shows the fluorescence expression level of NDV-GFP virus infected cells.
FIG. 8 shows the expression of GFP after infection of cells with NDV-GFP virus.
FIG. 9 shows VSV-G expression after infection of cells with VSV virus.
Detailed Description
The present application will now be described in further detail with reference to the drawings, it should be noted that the following detailed description is given for illustrative purposes only and is not to be construed as limiting the scope of the present application, as those skilled in the art will be able to make numerous insubstantial modifications and adaptations to the present application based on the above disclosure.
1. Material
The experimental procedures in the following examples are conventional biochemical procedures unless otherwise specified. The test materials used in the following examples were purchased from conventional biochemical reagent stores unless otherwise specified.
pSpCas9(BB) -2A-Puro vector was purchased from adddge (catalog number: PX 459);
DBT-1 cells: the product is a gift from military medical research institute of military science institute, and can be purchased through a market;
Opti-MEM I Medium: Gibco (Cat. No: 31985-;
liposomes (lipo 8000): biyuntian corporation (catalog number: C0533);
puromycin: gene Operation company (catalog number: ISY1130-0025 MG);
cisplatin: dalian Melam Biotechnology Ltd (catalog number: MB 1055);
psPAX2 vector, pCS-CG vector and pMD2.G vector: the product is offered by Qin light professor of the institute of Material science and information technology of Anhui university, and can also be purchased through a market approach;
newcastle disease virus NDV, vesicular stomatitis virus VSV: the product is a gift from military medical research institute of military science institute, and can be purchased from commercial sources.
The quantitative experiments in the following examples were set up in triplicate and the results averaged.
2. Method of producing a composite material
2.1 Effect of knockout cell lines on Lentiviral infection
2.1.1 sgRNA design
An open reading frame of a p53 gene [ NCBI accession number: 22059 ] in DBT-1 cells comprises 12 exons, 4 sgRNAs (sgRNAs 1-4) are screened and designed according to CRISPR-Cas9 technical requirements and sequence homology comparison analysis, the sgRNAs 1 target exon 1, the sgRNAs 2 and the sgRNAs 3 simultaneously target exon 4, and the sgRNAs 4 target exon 5. The target sequences of the four sgrnas are shown in table 1 below, and the positions on the p53 exon are shown in the results in fig. 1.
Table 1, 4 sgRNA target sequences
Name (R) | Sequence (5 '-3') |
sgRNA1 | CCTCGAGCTCCCTCTGAGCC |
sgRNA2 | AGTGAAGCCCTCCGAGTGTC |
sgRNA3 | TCCGAGTGTCAGGAGCTCCT |
sgRNA4 | CAGCGTGGTGGTACCTTATG |
2.1.2 recombinant plasmid construction
The DNA sequences and their complementary mating sequences in table 1 were synthesized separately, and the oligonucleotide double-stranded DNA sequences for constructing sgrnas are shown in table 2. After annealing, a double-stranded DNA molecule with cohesive ends at both ends was formed, and ligated to the vector pSpCas9(BB) -2A-Puro after Bpil digestion to obtain 4 recombinant plasmids (pSpCas9(BB) -2A-Puro-sgRNA1, pSpCas9(BB) -2A-Puro-sgRNA2, pSpCas9(BB) -2A-Puro-sgRNA3 and pSpCas9(BB) -2A-Puro-sgRNA 4).
Table 2, 4 recombinant plasmid insert sequences
2.1.3 cell transfection and protein expression detection
The 4 recombinant plasmids are transfected into DBT-1 cells, and the transfection method can be as follows:
(1) seeding DBT-1 cells into 6-well plates (density 1X 10)6One/well), 37 ℃ and 5% CO2The culture was carried out overnight in an incubator.
(2) The medium was discarded and replaced with fresh complete medium. 125. mu.l of Opti-MEM and 2.5. mu.g of the above 4 recombinant plasmids were added to each of 4 Ep tubes, and then gently pipetted and mixed. Mu.l of Lipo8000 transfection reagent was added and gently pipetted and mixed, and incubated at room temperature for 5 minutes. Finally, the mixture of plasmid and transfection reagent was added dropwise to the 6-well plate, and after 12 hours the incubation continued with fresh complete medium.
(3) After 24 hours, the medium was discarded and the cells were washed 3 times with PBS buffer, and the selection was performed by replacing the fresh medium containing puromycin. A portion of the cells collected after 1 week were subjected to immunoblotting to detect the expression of p53 protein and internal reference protein GAP DH, and the results are shown in FIG. 2. From the results, it can be seen that the expression of p53 in cells was significantly reduced after transfection of the plasmid pSpCas9(BB) -2A-Puro-sgRNA 2.
2.1.4 cell line screening and sequencing validation
The cell line stably expressing pSpCas9(BB) -2A-Puro-sgRNA2 was further screened. 3 knockout p53 monoclonal cells are finally obtained after 3 rounds of pressure screening and limiting dilution screening, and the immunoblotting result is shown in figure 3. After extracting cell genome, PCR amplifies p53 genome sequence containing sgRNA2 target region, PCR amplification primer 5 '-3' is:
F:CAGGGCAACTATGGCTTCCA;
R:AGGCACAAACACGAACCTCA。
after sequencing, the corresponding sequence in the 4 th exon of p53 is found to be edited into the sequences in the sequences 2, 3 and 4 through comparison, and compared with the DBT-1 cell original sequence shown in SEQ ID NO.1, the deletion or the addition of the base occurs, and the sequences 2, 3 and 4 are respectively shown as SEQ ID NO.2-4 in the sequence table.
2.1.5 identification of cell Activity and lentivirus infection
After obtaining the knockout cell, cell proliferation speed and anti-apoptosis detection are carried out. Inoculating 6000-8000 cells/well of control cells and knockout cells to a 96-well plate for normal culture, and performing MTT detection after 24 hours to obtain a result figure 4, wherein the proliferation speed of the knockout cells is higher; after counting the cells, the number of cells was 1X 105cells/mL were seeded into 6-well plates for 24 hours, and the experimental groups were starved with 3. mu.g/mL cisplatin or serum-free DMEM. After 48 hours the cells were rinsed twice with pre-cooled PBS and then 100. mu.l of 1 XBinding Buffer was added to resuspend the cells. Then 5 mul FITC-annexin V and 5 mul PI are added for shading and staining for 15 minutes, and after 300 mul 1 × binding Buffer is added, flow cytometry is carried out to detect the apoptosis level and the result is obtained as a figure 5, and it can be seen that the knockout cell shows obvious anti-apoptosis effect no matter the apoptosis inducer is cisplatin treated or is starved without serum.
Further, infection detection was performed by infecting cells with lentivirus. The general method for packaging the lentivirus comprises the following steps: 293T cells were seeded in 10cm dishes and after 24 hours the complete medium was changed to basal medium. The plasmid is diluted by a basal medium according to the proportion (pCS-CG: psPAX2: pMD2.G ═ 4:3:1), then is slowly blown and uniformly mixed, and the lipo8000 transfection reagent is diluted by the basal medium, then is dripped into the plasmid mixed liquor, and is gently mixed, and is kept stand for 20 minutes. The solution is uniformly dripped into a cell culture dish, and after the culture is continued for 6 to 8 hours, the culture medium is replaced by a complete culture medium. After 48 and 72 hours, respectively, the green fluorescence intensity was observed under a fluorescence microscope and the culture broth was collected in a sterile centrifuge tube. And (3) carrying out centrifugal filtration on the collected cell culture solution, standing overnight, centrifuging, discarding supernatant, and then carrying out heavy suspension precipitation on the supernatant by using a basic culture medium to obtain concentrated virus solution.
The general steps for lentivirus infection of cells are: inoculation of 1X 106DBT-1 cells were infected in 6-well plates, and the next day when cell density was observed to be around 70%. Virus liquid was cultured in complete medium at 1: 50 dilution is carried out for cell infection, liquid is changed after 24 hours, cells are collected under a fluorescence microscope after 48 hours, and the fluorescence intensity is detected by using a flow cytometer to obtain a result figure 6, and the result shows that the proliferation of lentivirus can be remarkably promoted after the gene p53 is knocked out.
2.2 Effect of knockout cell lines on amplification of NDV-GFP Virus
After a p53 knockout cell is obtained, NDV-GFP virus is used for infecting the cell, the virus is verified by detecting the expression condition of green fluorescent protein after Green Fluorescent Protein (GFP) gene is inserted into NDV virus genome to construct expression recombinant NDV, and the general steps are as follows: inoculation of 1X 106Every well of DBT-1 cells was in 6-well plates, and the next day when cell density reached around 70%, the total culture medium was used at 1: the NDV-GFP virus solution was diluted 800 to infect cells. After infection for 6 hours, the liquid is changed, after 12 hours, the fluorescence expression condition is observed under a fluorescence microscope or the expression condition of GFP and internal reference protein beta-tubulin is detected by collecting cells through an immunoblotting experiment, and the results are shown in fig. 7 and 8, and the result shows that the proliferation of NDV-GFP virus can be remarkably promoted after p53 is knocked out.
2.3 Effect of knockout cell lines on VSV Virus amplification
As above, when cells are infected with VSV, since the G protein is the major surface antigen of the virus, it can be confirmed by detecting the expression of VSV-G protein, and the results are summarizedThe method comprises the following steps: inoculation of 1X 106Individual/well DBT-1 cells in 6-well plates, next day cell density to around 70%, run out of whole medium as 1: VSV virus solution was diluted 1500 for cell infection. After infection for 3 hours, the cells were replaced, and 18 hours later, the expression of VSV-G protein and internal reference protein GAPDH was detected by immunoblotting, and FIG. 9 shows the results, from which it can be seen that the knock-out of p53 also promotes the proliferation of the virus.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is specific and detailed, but not to be understood as limiting the scope of the present invention. It should be noted that various changes and modifications can be made by those skilled in the art without departing from the spirit of the invention, and these changes and modifications are all within the scope of the invention.
Sequence listing
<110> university of Anhui
<120> recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof
<141> 2022-01-17
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 261
<212> DNA
<213> mouse (Muridae)
<400> 1
ccatcacctc actgcatgga cgatctgttg ctgccccagg atgttgagga gttttttgaa 60
ggcccaagtg aagccctccg agtgtcagga gctcctgcag cacaggaccc tgtcaccgag 120
acccctgggc cagtggcccc tgccccagcc actccatggc ccctgtcatc ttttgtccct 180
tctcaaaaaa cttaccaggg caactatggc ttccacctgg gcttcctgca gtctgggaca 240
gccaagtctg ttatgtgcac g 261
<210> 2
<211> 231
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ccatcacctc actccatgga cgatctgttg ctgccccagg atgttgagga gttttttgaa 60
ggcccaagtg aagccctcca atacttattg aaggtgtcag gagctcctgc agcacaggac 120
cctgtcactg agacccctgg gccagtggcc cctgccccag ctactccatg gcccccgtca 180
tcttttgccc cttctcaaaa aacttaccag gggaactatg gcttcaaggg c 231
<210> 3
<211> 236
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ccatcacctc actccatgga cgatctgttg ctgccccagg atgttgagga gttttttgaa 60
ggcccaagtg aagccctcca agtcaggagc tcctgcagca caggaccctg tcactgagac 120
ccctgggcca gtggcccctg ccccagctac tccatggccc ccgtcatctt ttgtcccttc 180
tcaaaaaact taccagggca actatggctt caagggcgac acgcgattgc agtctt 236
<210> 4
<211> 274
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ccatcacctc actccatgga cgatctgttg ctgccccagg atgttgagga gttttttgaa 60
ggcccaagtg aagccctcca agttgtcagg agctcctgca gcacaggacc ctgtcactga 120
gacccctggg ccagtggccc ctgccccagc tactccatgg cccccgtcat cttttgcccc 180
ttctcaaaaa acttaccagg gcaactatgg cttcaagggc gacacgcgat tgcagtcttg 240
agtccacctg aaggatgtca aacttggtca tagc 274
Claims (10)
1. A recombinant cell for efficiently amplifying RNA viruses is a eukaryotic cell with deleted expression of a p53 gene, wherein the eukaryotic cell is prepared by inactivating the p53 gene in the eukaryotic cell.
2. The recombinant cell of claim 1, wherein the eukaryotic cell is a DBT-1 cell.
3. The recombinant cell according to claim 1, wherein the recombinant cell is characterized in that the 4 th exon sequence of the p53 gene is mutated, the 4 th exon sequence comprises the nucleotide sequence shown in SEQ ID No.1, and the mutation is deletion or addition of at least 1 base in the nucleotide sequence shown in SEQ ID No. 1.
4. The recombinant cell of claim 1, wherein the mutation is a nucleotide sequence as set forth in SEQ ID No.1 edited to a sequence as set forth in any one of SEQ ID nos. 2-4.
5. The recombinant cell of claim 1, wherein the p53 gene in the eukaryotic cell is inactivated by gene knockout using CRISPR-Cas9 technology, comprising the steps of:
(1) the coding region of an exon of a eukaryotic cell p53 gene is used as a template, and a specifically targeted sgRNA sequence is designed according to CRISPR-Cas9 technical requirements and sequence homology comparison analysis;
(2) synthesizing double-stranded DNA of knockout p53 according to the sgRNA sequence, and connecting the double-stranded DNA to pSpCas9(BB) -2A-Puro plasmid to obtain a recombinant plasmid;
(3) transfecting the recombinant plasmid into a eukaryotic cell, and screening a cell strain with significantly reduced expression of p 53;
(4) and (3) obtaining the monoclonal cell with p53 knocked out by a pressure screening and limiting dilution method, namely the recombinant cell.
6. The recombinant cell of claim 5, wherein the eukaryotic cell is a DBT-1 cell, the sequence of the sgRNA specifically targeted in step (1) is 5'-AGTGAAGCCCTCCGAGTGTC-3', and the sequence of the double-stranded DNA in step (2) is oligo 1: 5'-CACCGCCTCGAGCTCCCTCTGAGCC-3', respectively; oligo 2: 5'-AAACGGCTCAGAGGGAGCTCGAGGC-3' are provided.
7. A method for efficiently amplifying RNA viruses according to any one of claims 1 to 6, wherein the recombinant cells are infected with a virus to increase the titer of the virus, thereby achieving efficient amplification.
8. The method of claim 4, wherein the RNA virus is a lentivirus.
9. The method for highly amplifying an RNA virus of claim 4, wherein the lentivirus is VSV virus or NDV virus.
10. Use of the recombinant cell of claim 1 for the efficient amplification of RNA viruses and their use in the production and development of vaccines for said RNA viruses.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210047605.0A CN114540309A (en) | 2022-01-17 | 2022-01-17 | Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210047605.0A CN114540309A (en) | 2022-01-17 | 2022-01-17 | Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114540309A true CN114540309A (en) | 2022-05-27 |
Family
ID=81672405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210047605.0A Pending CN114540309A (en) | 2022-01-17 | 2022-01-17 | Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114540309A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117802097A (en) * | 2023-12-05 | 2024-04-02 | 北京蒙微生物科技有限公司 | sgRNA for knocking out ISG15 gene, ISG15 gene-deleted bovine kidney cell and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101835890A (en) * | 2008-06-27 | 2010-09-15 | 国立大学法人京都大学 | Method of efficiently establishing induced pluripotent stem cells |
CN102071196A (en) * | 2009-11-24 | 2011-05-25 | 中国农业科学院上海兽医研究所 | SiRNA for inhibiting canine p53 gene expression and canine cell model of p53 gene silence |
US20140088177A1 (en) * | 2001-07-11 | 2014-03-27 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
-
2022
- 2022-01-17 CN CN202210047605.0A patent/CN114540309A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140088177A1 (en) * | 2001-07-11 | 2014-03-27 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
CN101835890A (en) * | 2008-06-27 | 2010-09-15 | 国立大学法人京都大学 | Method of efficiently establishing induced pluripotent stem cells |
CN102071196A (en) * | 2009-11-24 | 2011-05-25 | 中国农业科学院上海兽医研究所 | SiRNA for inhibiting canine p53 gene expression and canine cell model of p53 gene silence |
Non-Patent Citations (1)
Title |
---|
YOSHITAKA SATO ET AL.: "Genome guardian p53 and viral infections", REV. MED. VIROL., vol. 23, pages 215 - 217 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117802097A (en) * | 2023-12-05 | 2024-04-02 | 北京蒙微生物科技有限公司 | sgRNA for knocking out ISG15 gene, ISG15 gene-deleted bovine kidney cell and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112020008201A2 (en) | target replacement of endogenous t cell receptors | |
WO2019214290A1 (en) | METHOD FOR PRODUCING γδ T CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR | |
CN109810953A (en) | The recombination the Temple of Heaven strain oncolytic vaccinia virus of removal TK gene and its preparation and application | |
JP6956416B2 (en) | Transposon system, kits containing it and their use | |
WO2022147759A1 (en) | Grna molecule targeting intron i or intron ii of hbb gene, synthetic method thereof, and method to correct types of hbb gene mutations | |
CN116694574B (en) | HLA-A and HLA-B co-knocked-out multiple blood lineage differentiation potential immortalized cell and manufacturing method thereof | |
CN112899237A (en) | CDKN1A gene reporter cell line and construction method and application thereof | |
CN110093376B (en) | Construction method of LRFFT1 cells | |
CN114540309A (en) | Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof | |
CN104694576A (en) | Method for silencing IFNARI gene in DF-1 cell line | |
CN113226336B (en) | Method for delivering genes in cells | |
WO2016015684A1 (en) | Nrecombinant adeno-associated virus vector carrying human papillomavirus type 16 mutation e7 antigen gene, construction method therefor, and application thereof | |
JP2023520083A (en) | Active DNA transposon system and method of use thereof | |
CN113308470A (en) | sgRNA of targeted ARID1A gene knockout, method for constructing ARID1A gene deletion cell strain and application | |
CN108239620A (en) | The mdck cell strain of 1 encoding gene of IFN-β missing and its construction method and application | |
CN117126855A (en) | Method for constructing Igf2bp1 gene knockout mouse embryonic stem cell line | |
CN110205304A (en) | A kind of recombination the Temple of Heaven strain oncolytic vaccinia virus and preparation method and application | |
WO2021197506A1 (en) | Recombinant newcastle disease virus and preparation method, recombinant plasmid, and use therefor | |
CN109294997B (en) | LRFFT1 cell | |
CN111876385A (en) | Construction method and application of mouse lung cancer KRAS mutant cell model | |
JP6855579B2 (en) | Methods and uses to obtain T cells | |
CN118546935B (en) | Method for preparing enhanced CAR-T cells based on interference or knocked-out human PCSK9 gene and application | |
CN111378690A (en) | Preparation method of chimeric antigen receptor T cell | |
Heyn et al. | Self-Repairing Herpesvirus Saimiri Deletion Variants | |
CN115772504A (en) | Recombinant cell for efficiently amplifying RNA virus, and amplification method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220527 |